Atogepant

EN Texto em inglês Ainda não há artigo no teu idioma: trecho em inglês.

Atogepant, sold under the brand name Qulipta among others, is a medication used to prevent migraines. It is a gepant, a calcitonin gene-related peptide receptor antagonist administered orally. The most common side effects include nausea, constipation, tiredness, somnolence (sleepiness), decreased appetite, and decreased weight. Atogepant was approved for medical use in the United States in September 2021, and in the European Union in August 2023. Atogepant is indicated for the preventive treatment of episodic migraine in adults. In the European Union, atogepant (Aquipta) is indicated for prophylaxis (prevention) of migraine in adults who have at least four migraine days per month. Atogepant was developed by the biopharmaceutical company AbbVie. The benefits and side effects of atogepant were evaluated in two clinical trials of 1,562 participants with a history of migraine headaches occurring on 4 to 14 days per month. The two trials to show the benefits were designed similarly. Trials 1 and 2 assigned participants to one of several doses of atogepant or placebo daily for three months.